tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cormedix: Near-Term Reimbursement Headwinds but Compelling Long-Term Upside Supports Buy Rating and $18 Target
PremiumRatingsCormedix: Near-Term Reimbursement Headwinds but Compelling Long-Term Upside Supports Buy Rating and $18 Target
28d ago
Cormedix: Market Overreaction to 2026 Guidance Creates Undervalued Buy Opportunity
Premium
Ratings
Cormedix: Market Overreaction to 2026 Guidance Creates Undervalued Buy Opportunity
28d ago
CorMedix price target lowered to $16 from $20 at Truist
Premium
The Fly
CorMedix price target lowered to $16 from $20 at Truist
29d ago
CorMedix appoints Mike Seckler as CCO
PremiumThe FlyCorMedix appoints Mike Seckler as CCO
29d ago
CorMedix sees Q4 revenue $127M, consensus $127.52M
Premium
The Fly
CorMedix sees Q4 revenue $127M, consensus $127.52M
29d ago
DefenCath’s Strong Clinical and Economic Profile Underpins Buy Rating Despite Anticipated 2026 Pricing Headwinds
Premium
Ratings
DefenCath’s Strong Clinical and Economic Profile Underpins Buy Rating Despite Anticipated 2026 Pricing Headwinds
2M ago
CorMedix Inc. Reports Record Earnings and Strategic Growth
PremiumCompany AnnouncementsCorMedix Inc. Reports Record Earnings and Strategic Growth
3M ago
Cormedix: Buy Rating Affirmed Amid Strong Sales and Future Growth Catalysts
Premium
Ratings
Cormedix: Buy Rating Affirmed Amid Strong Sales and Future Growth Catalysts
3M ago
CorMedix reports Q3 EPS $1.26, consensus 63c
Premium
The Fly
CorMedix reports Q3 EPS $1.26, consensus 63c
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100